Kalymin

Pyridostigmine bromide, the active ingredient in Kalymin, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel function after surgery. GNH USA supplies Kalymin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kalymin, an acetylcholinesterase inhibitor, is used in conditions where enhanced cholinergic transmission is therapeutic.

Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. Postoperative ileus: stimulates gastrointestinal motility, facilitating return of normal bowel activity.

Adverse reactions may occur with pyridostigmine bromide therapy.

Common Side Effects: - Nausea and vomiting - Diarrhea or abdominal cramps - Increased salivation and sweating - Muscle cramps or fasciculations - Blurred vision or increased urinary frequency

Serious or Rare Side Effects: - Cholinergic crisis with severe muscle weakness - Bronchospasm or respiratory difficulty - Cardiac arrhythmias or severe hypotension - Anaphylactic or severe allergic reactions - Worsening of myasthenic symptoms

When prescribing Kalymin, clinicians should consider several safety measures.

Dose adjustment in renal impairment: reduce dose according to renal function. Monitor for signs of cholinergic excess: sweating, salivation, gastrointestinal upset. Caution in patients with asthma or COPD: may exacerbate bronchospasm. Avoid abrupt discontinuation: may precipitate myasthenic crisis. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from moisture and light.

Pyridostigmine bromide can interact with several drug classes.

Major Interactions (Avoid): - Anticholinergic agents: may reduce therapeutic effect. - Beta‑adrenergic blockers: may potentiate cholinergic activity. - Magnesium‑containing antacids: may impair drug absorption. - Non‑depolarizing neuromuscular blockers: may enhance neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: may increase cholinergic side effects. - Cardiac glycosides: may raise risk of bradycardia. - Other cholinesterase inhibitors: additive cholinergic effects.